Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US. Basaglar will also undercut Sanofi ...

Sanofi sues Eli Lilly over challenge to top diabetes drug Lantus (Reuters). Reference links: Sanofi files suit in the US to defend its patent rights (Sanofi press release, PDF).

John Kell wrote about general corporate news and major market movers.